NO984757L - Gliacellelinjeavledet, neurotropisk faktorreseptor - Google Patents
Gliacellelinjeavledet, neurotropisk faktorreseptorInfo
- Publication number
- NO984757L NO984757L NO984757A NO984757A NO984757L NO 984757 L NO984757 L NO 984757L NO 984757 A NO984757 A NO 984757A NO 984757 A NO984757 A NO 984757A NO 984757 L NO984757 L NO 984757L
- Authority
- NO
- Norway
- Prior art keywords
- gdnf
- gdnfr
- receptor
- nervous system
- present
- Prior art date
Links
- 210000004498 neuroglial cell Anatomy 0.000 title 1
- 239000003076 neurotropic agent Substances 0.000 title 1
- 102000004216 Glial cell line-derived neurotrophic factor receptors Human genes 0.000 abstract 5
- 108090000722 Glial cell line-derived neurotrophic factor receptors Proteins 0.000 abstract 5
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 abstract 4
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 abstract 4
- 102000005962 receptors Human genes 0.000 abstract 3
- 108020003175 receptors Proteins 0.000 abstract 3
- 230000002209 hydrophobic effect Effects 0.000 abstract 2
- 108010025020 Nerve Growth Factor Proteins 0.000 abstract 1
- 102000007072 Nerve Growth Factors Human genes 0.000 abstract 1
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 238000010367 cloning Methods 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 230000001086 cytosolic effect Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1590796P | 1996-04-22 | 1996-04-22 | |
| US1722196P | 1996-05-09 | 1996-05-09 | |
| US08/837,199 US6455277B1 (en) | 1996-04-22 | 1997-04-14 | Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides |
| PCT/US1997/006281 WO1997040152A1 (fr) | 1996-04-22 | 1997-04-15 | Recepteur de gdnf |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO984757D0 NO984757D0 (no) | 1998-10-12 |
| NO984757L true NO984757L (no) | 1998-12-21 |
Family
ID=27360445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO984757A NO984757L (no) | 1996-04-22 | 1998-10-12 | Gliacellelinjeavledet, neurotropisk faktorreseptor |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US6455277B1 (fr) |
| EP (1) | EP0909316B1 (fr) |
| JP (1) | JP2000509271A (fr) |
| KR (1) | KR20000010571A (fr) |
| CN (1) | CN1219967A (fr) |
| AT (1) | ATE338115T1 (fr) |
| AU (1) | AU720092B2 (fr) |
| BR (1) | BR9708959A (fr) |
| CA (1) | CA2250704C (fr) |
| CZ (1) | CZ324598A3 (fr) |
| DE (1) | DE69736597T2 (fr) |
| EA (1) | EA002924B1 (fr) |
| ES (1) | ES2271968T3 (fr) |
| HU (1) | HUP9902640A3 (fr) |
| IL (1) | IL126553A0 (fr) |
| NO (1) | NO984757L (fr) |
| NZ (1) | NZ332256A (fr) |
| SK (1) | SK140398A3 (fr) |
| WO (1) | WO1997040152A1 (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6696259B1 (en) * | 1995-11-13 | 2004-02-24 | Licentia Ltd. | Assays using glial cell line-derived neurotrophic factor receptors |
| WO1997044356A2 (fr) * | 1996-05-08 | 1997-11-27 | Biogen, Inc. | Test diagnostique de detection de la schizophrenie faisant appel a de la miacine |
| US6677135B1 (en) * | 1996-05-08 | 2004-01-13 | Biogen, Inc. | Ret ligand (RetL) for stimulating neutral and renal growth |
| US20020068361A1 (en) * | 1997-04-08 | 2002-06-06 | Douglas Clary | Methods of evaluating specific cellular functions of receptor protein tyrosine kinases in a ligand independent manner |
| AU7165998A (en) * | 1997-05-30 | 1998-12-30 | Amgen, Inc. | Neurotrophic factor receptors |
| US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
| DE19816186A1 (de) * | 1998-04-14 | 1999-10-21 | Univ Muenchen L Maximilians | GDNF-kodierende DNA, Teile davon und GDNF-Varianten |
| FI20000394A0 (fi) * | 2000-02-21 | 2000-02-21 | Airaksinen Matti | GFRa4:n sukuisia tai siitä johdettuja aineita sekä niiden käyttö |
| WO2004085648A2 (fr) | 2003-03-19 | 2004-10-07 | Biogen Idec Ma Inc. | Proteine de liaison de recepteur de nogo |
| CN1897977A (zh) * | 2003-10-20 | 2007-01-17 | Ns基因公司 | 帕金森氏病的体内基因治疗 |
| AU2005258335B2 (en) | 2004-06-24 | 2011-03-17 | Biogen Ma Inc. | Treatment of conditions involving demyelination |
| CA2583308C (fr) * | 2004-10-08 | 2020-01-07 | Georgia Tech Research Corporation | Microencapsulation de cellules dans des hydrogels a l'aide de potentiels electrostatiques |
| SG163591A1 (en) | 2005-07-08 | 2010-08-30 | Biogen Idec Inc | Sp35 antibodies and uses thereof |
| AU2006311828B2 (en) * | 2005-11-04 | 2013-07-11 | Biogen Ma Inc. | Methods for promoting neurite outgrowth and survival of dopaminergic neurons |
| DK2982695T3 (da) | 2008-07-09 | 2019-05-13 | Biogen Ma Inc | Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf |
| WO2013173364A2 (fr) | 2012-05-14 | 2013-11-21 | Biogen Idec Ma Inc. | Antagonistes de lingo-2 pour le traitement d'affections impliquant des neurones moteurs |
| WO2016112270A1 (fr) | 2015-01-08 | 2016-07-14 | Biogen Ma Inc. | Antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation |
| AU2017357931A1 (en) | 2016-11-10 | 2019-06-20 | Keros Therapeutics, Inc. | GDNF fusion polypeptides and methods of use thereof |
| RU2690498C1 (ru) * | 2018-05-17 | 2019-06-04 | Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр" | Способ получения ноотропной композиции на основе полипептидных комплексов, выделенных из нейронов и глиальных клеток, полученных методом направленной дифференцировки индуцированных плюрипотентных стволовых клеток человека |
| RU2732600C1 (ru) * | 2019-12-26 | 2020-09-21 | Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр имени академика Н.П. Бочкова" | Ноотропная композиция на основе полипептидных комплексов, выделенных из нейрональных прогениторных клеток в условиях гипоксии, и способ ее получения |
| RU2752906C2 (ru) * | 2019-12-26 | 2021-08-11 | Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр имени академика Н.П. Бочкова" | Ноотропная композиция на основе полипептидных комплексов, выделенных из нейрональных прогениторных клеток в условиях теплового шока, и способ ее получения |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
| WO1990014363A1 (fr) | 1989-05-19 | 1990-11-29 | Amgen Inc. | Inhibiteur de metalloproteinase |
| HU220795B1 (hu) | 1991-09-20 | 2002-05-28 | Amgen Inc. | Gliasejtvonal-eredetű neurotróf faktorfehérjék, továbbá berendezések és gyógyászati készítmények idegsejtkárosodás megelőzésére és kezelésére |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
-
1997
- 1997-04-14 US US08/837,199 patent/US6455277B1/en not_active Expired - Lifetime
- 1997-04-15 JP JP9538155A patent/JP2000509271A/ja not_active Ceased
- 1997-04-15 EA EA199800933A patent/EA002924B1/ru not_active IP Right Cessation
- 1997-04-15 CZ CZ983245A patent/CZ324598A3/cs unknown
- 1997-04-15 IL IL12655397A patent/IL126553A0/xx unknown
- 1997-04-15 AT AT97921203T patent/ATE338115T1/de not_active IP Right Cessation
- 1997-04-15 NZ NZ332256A patent/NZ332256A/xx unknown
- 1997-04-15 HU HU9902640A patent/HUP9902640A3/hu unknown
- 1997-04-15 CA CA002250704A patent/CA2250704C/fr not_active Expired - Fee Related
- 1997-04-15 AU AU27309/97A patent/AU720092B2/en not_active Ceased
- 1997-04-15 EP EP97921203A patent/EP0909316B1/fr not_active Expired - Lifetime
- 1997-04-15 WO PCT/US1997/006281 patent/WO1997040152A1/fr active IP Right Grant
- 1997-04-15 ES ES97921203T patent/ES2271968T3/es not_active Expired - Lifetime
- 1997-04-15 BR BR9708959A patent/BR9708959A/pt not_active Application Discontinuation
- 1997-04-15 CN CN97194013A patent/CN1219967A/zh active Pending
- 1997-04-15 KR KR1019980708430A patent/KR20000010571A/ko active IP Right Grant
- 1997-04-15 DE DE69736597T patent/DE69736597T2/de not_active Expired - Lifetime
- 1997-04-15 SK SK1403-98A patent/SK140398A3/sk unknown
-
1998
- 1998-10-12 NO NO984757A patent/NO984757L/no not_active Application Discontinuation
-
2002
- 2002-05-24 US US10/155,693 patent/US20030175876A1/en not_active Abandoned
-
2006
- 2006-01-12 US US11/332,638 patent/US20060166325A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2250704A1 (fr) | 1997-10-30 |
| JP2000509271A (ja) | 2000-07-25 |
| ES2271968T3 (es) | 2007-04-16 |
| US6455277B1 (en) | 2002-09-24 |
| HUP9902640A2 (hu) | 1999-11-29 |
| IL126553A0 (en) | 1999-08-17 |
| SK140398A3 (en) | 1999-04-13 |
| BR9708959A (pt) | 1999-08-03 |
| CZ324598A3 (cs) | 1999-01-13 |
| AU720092B2 (en) | 2000-05-25 |
| NO984757D0 (no) | 1998-10-12 |
| EP0909316A1 (fr) | 1999-04-21 |
| US20030175876A1 (en) | 2003-09-18 |
| AU2730997A (en) | 1997-11-12 |
| CA2250704C (fr) | 2005-04-12 |
| EA199800933A1 (ru) | 1999-04-29 |
| EP0909316B1 (fr) | 2006-08-30 |
| DE69736597D1 (de) | 2006-10-12 |
| HUP9902640A3 (en) | 2001-11-28 |
| DE69736597T2 (de) | 2006-12-21 |
| CN1219967A (zh) | 1999-06-16 |
| NZ332256A (en) | 2000-03-27 |
| EA002924B1 (ru) | 2002-10-31 |
| ATE338115T1 (de) | 2006-09-15 |
| WO1997040152A1 (fr) | 1997-10-30 |
| KR20000010571A (ko) | 2000-02-15 |
| US20060166325A1 (en) | 2006-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO984757L (no) | Gliacellelinjeavledet, neurotropisk faktorreseptor | |
| Borroto-Escuela et al. | Evidence for the existence of FGFR1–5-HT1A heteroreceptor complexes in the midbrain raphe 5-HT system | |
| Borasio et al. | Involvement of ras p21 in neurotrophin-induced response of sensory, but not sympathetic neurons. | |
| Wu et al. | The coming of age of axonal neurotrophin signaling endosomes | |
| Seth et al. | Expression pattern of the type 1 sigma receptor in the brain and identity of critical anionic amino acid residues in the ligand-binding domain of the receptor | |
| Yap et al. | Adaptor protein complex-4 (AP-4) is expressed in the central nervous system neurons and interacts with glutamate receptor δ2 | |
| Hoy et al. | SynCAM1 recruits NMDA receptors via protein 4.1 B | |
| Thompson et al. | Overexpression of the GABAA receptor ε subunit results in insensitivity to anaesthetics | |
| Murcia‐Belmonte et al. | Biochemical dissection of Anosmin‐1 interaction with FGFR1 and components of the extracellular matrix | |
| Luberg et al. | Novel transcripts reveal a complex structure of the human TRKA gene and imply the presence of multiple protein isoforms | |
| Feldman et al. | Characterization of acid‐sensing ion channel expression in oligodendrocyte‐lineage cells | |
| KR20220110556A (ko) | 생리 활성을 갖는 펩타이드의 제조 방법 및 단쇄 링커를 포함하는 펩타이드 | |
| Godeny et al. | The N-terminal SH2 domain of the tyrosine phosphatase, SHP-2, is essential for Jak2-dependent signaling via the angiotensin II type AT1 receptor | |
| CA2414355A1 (fr) | Peptides lineaires amphipathiques et les compositions les contenant | |
| WO1998054213A3 (fr) | Recepteurs du facteur neurotrope | |
| Tereshko et al. | Primary cilia in the postnatal brain: Subcellular compartments for organizing neuromodulatory signaling | |
| Ramasamy et al. | NogoR1 and PirB signaling stimulates neural stem cell survival and proliferation | |
| MACDONALD | Mechanisms of action | |
| Fukusumi et al. | Therapeutic target for nephrotic syndrome: Identification of novel slit diaphragm associated molecules | |
| WO1998054213B1 (fr) | Recepteurs du facteur neurotrope | |
| Reynolds et al. | Developmental expression of functional GABAA receptors containing the γ2 subunit in neurons derived from embryonal carcinoma (P19) cells | |
| Nakanishi et al. | Determination of ionization efficiency of glycated and non-glycated peptides from the N-terminal of hemoglobin β-chain by electrospray ionization mass spectrometry | |
| Einarsen et al. | Functional properties of human neuronal Kv11 channels | |
| NL2033185B1 (en) | Compounds for rna stabilisation and delivery | |
| WO2023054659A1 (fr) | Procédé de production d'organoïdes, milieu de culture pour la production d'organoïdes, organoïde et procédé d'évaluation de substance d'essai |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |